{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:29:22Z","timestamp":1761560962652},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1016\/j.det.2004.03.014","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T14:53:34Z","timestamp":1113836014000},"page":"407-426","source":"Crossref","is-referenced-by-count":19,"title":["Current concepts and review of alefacept in the treatment of psoriasis"],"prefix":"10.1016","volume":"22","author":[{"given":"Gerald G.","family":"Krueger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.det.2004.03.014_BIB1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00128071-200304040-00006","article-title":"Alefacept","volume":"4","author":"Frampton","year":"2003","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.det.2004.03.014_BIB2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1540-9740.2003.01869.x","article-title":"Evolution of biologic therapies for the treatment of psoriasis","volume":"2","author":"Gordon","year":"2003","journal-title":"SKINmed: Dermatol Clinician"},{"issue":"2","key":"10.1016\/j.det.2004.03.014_BIB3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1006\/clim.2002.5289","article-title":"Recombinantly engineered human proteins: transforming the treatment of psoriasis","volume":"105","author":"Gottlieb","year":"2002","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1016\/j.det.2004.03.014_BIB4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1517\/14712598.2.4.431","article-title":"Selective targeting of T cell subsets: focus on alefacept\u2014a remittive therapy for psoriasis","volume":"2","author":"Krueger","year":"2002","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.det.2004.03.014_BIB5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1468-3083.2003.00720.x","article-title":"The role of T cells in psoriasis","volume":"17","author":"Prinz","year":"2003","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.det.2004.03.014_BIB6","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/eji.200323586","article-title":"Alefacept selectively promotes NK cell-mediated deletion of CD45RO+ human T cells","volume":"33","author":"Cooper","year":"2003","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.det.2004.03.014_BIB7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/15419069909010808","article-title":"Low affinity binding of an LFA-3\/IgG1 fusion protein to CD2+ T cells is independent of cell activation","volume":"7","author":"Majeau","year":"1999","journal-title":"Cell Adhes Commun"},{"issue":"5","key":"10.1016\/j.det.2004.03.014_BIB8","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.4049\/jimmunol.140.5.1401","article-title":"Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-\u03b3 production","volume":"140","author":"Sanders","year":"1988","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.det.2004.03.014_BIB9","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.4049\/jimmunol.152.6.2753","article-title":"Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure\/function analysis in vitro and in human CD2 transgenic mice","volume":"152","author":"Majeau","year":"1994","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.det.2004.03.014_BIB10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.178.1.211","article-title":"Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses","volume":"178","author":"Miller","year":"1993","journal-title":"J Exp Med"},{"issue":"9","key":"10.1016\/j.det.2004.03.014_BIB11","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.4049\/jimmunol.168.9.4462","article-title":"Alefacept, an immunomodulatory recombinant LFA-3\/IgG1 fusion protein, induces CD16 signaling and CD2\/CD16-dependent apoptosis of CD2+ cells","volume":"168","author":"da Silva","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.det.2004.03.014_BIB12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJM200107263450403","article-title":"Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes","volume":"345","author":"Ellis","year":"2001","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.det.2004.03.014_BIB13","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1067\/mjd.2002.127247","article-title":"A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis","volume":"47","author":"Krueger","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.det.2004.03.014_BIB14","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.139.6.719","article-title":"An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis","volume":"139","author":"Lebwohl","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2004.03.014_BIB15","first-page":"344","article-title":"Efficacy and safety of multiple courses of intramuscular alefacept in patients with chronic plaque psoriasis [abstract]","volume":"119","author":"Langley","year":"2002","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.det.2004.03.014_BIB16","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis\u2014oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1016\/j.det.2004.03.014_BIB17","unstructured":"Vaishnaw A.K., Ticho B. Alefacept is efficacious in a broad spectrum of patients with psoriasis, including those with severe disease. Presented at the 61st Annual Meeting of the American Academy of Dermatology. San Francisco, March 21\u201326, 2003"},{"issue":"Suppl 1","key":"10.1016\/j.det.2004.03.014_BIB18","first-page":"55","article-title":"Alefacept is efficacious in a broad spectrum of patients with psoriasis","volume":"17","author":"van de Kerkhof","year":"2003","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2004.03.014_BIB19","unstructured":"Christophers E., O'Gorman J., Vaishnaw A.K. Pooled efficacy of alefacept in psoriasis patients who are refractory or have contraindications to other psoriasis systemic treatments or phototherapies. Presented at the Ninth International Psoriasis Symposium. New York, June 18\u201322, 2003"},{"key":"10.1016\/j.det.2004.03.014_BIB20","first-page":"624","article-title":"Remittive effects of intramuscular alefacept in psoriasis","volume":"2","author":"Gordon","year":"2003","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.det.2004.03.014_BIB21","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/archderm.139.12.1563","article-title":"Treatment of psoriasis with alefacept. Correlation of clinical improvement with reductions of memory T-cell counts","volume":"139","author":"Gordon","year":"2003","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.det.2004.03.014_BIB22","first-page":"117","article-title":"Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis","volume":"13","author":"Ortonne","year":"2003","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.det.2004.03.014_BIB23","first-page":"1077","article-title":"Therapeutic improvement induced by alefacept is linked to selective elimination of CD3+, CD8+ and CD103+ T cells from skin lesions of psoriasis vulgaris [abstract 88]","volume":"147","author":"Chamian","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2004.03.014_BIB24","unstructured":"Vaishnaw A.K., Lee S. Concomitant use of alefacept and immunosuppressants in patients with psoriasis. Presented at the 61st Annual Meeting of the American Academy of Dermatology. San Francisco, March 21\u201326, 2003"},{"key":"10.1016\/j.det.2004.03.014_BIB25","unstructured":"Lebwohl M., Vaishnaw A.K. Variability in circulating T-cell subsets among alefacept-treated and placebo-treated patients with psoriasis. Presented at Academy '03. Chicago, July 25\u201329, 2003"},{"issue":"3","key":"10.1016\/j.det.2004.03.014_BIB26","first-page":"280","article-title":"The impact of psoriasis on quality of life. Results of a 1998 National Psoriasis Foundation patient-membership survey","volume":"137","author":"Krueger","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2004.03.014_BIB27","unstructured":"Salonen S.H., for the EUROPSO Patient Survey Study Group. The EUROPSO psoriasis patient survey: first results from 17,990 association members with psoriasis. Presented at the Ninth International Psoriasis Symposium. New York, June 18\u201322, 2003"},{"key":"10.1016\/j.det.2004.03.014_BIB28","unstructured":"Salonen S.H., for the EUROPSO Patient Survey Study Group. The EUROPSO psoriasis patient survey: treatment history and satisfaction. Presented at the Ninth International Psoriasis Symposium. New York, June 18\u201322, 2003"},{"key":"10.1016\/j.det.2004.03.014_BIB29","unstructured":"O'Gorman J., Vaishnaw A. Lack of correlation between the quality of life (QOL) of psoriasis patients and objective measures of disease severity: an integrated analysis of phase 3 studies. Presented at Academy '03. Chicago, July 25\u201329, 2003"},{"issue":"3","key":"10.1016\/j.det.2004.03.014_BIB30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.det.2004.03.014_BIB31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00128071-200304020-00005","article-title":"Effects of alefacept on health-related quality of life in patients with psoriasis. Results from a randomized, placebo-controlled phase II trial","volume":"4","author":"Ellis","year":"2003","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.det.2004.03.014_BIB32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2133.2004.05697.x","article-title":"Improved health-related quality of life following alefacept treatment in patients with chronic plaque psoriasis","volume":"150","author":"Feldman","year":"2004","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2004.03.014_BIB33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000069942","article-title":"Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis","volume":"206","author":"Finlay","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.det.2004.03.014_BIB34","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jaad.2003.09.014","article-title":"A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis","volume":"50","author":"Carlin","year":"2004","journal-title":"J Amer Acad Dermatol"},{"key":"10.1016\/j.det.2004.03.014_BIB35","first-page":"244","article-title":"Reduction of CD45RO+ effector T lymphocytes is not observed in the treatment of psoriasis with methotrexate [abstract]","volume":"119","author":"Callis","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.det.2004.03.014_BIB36","unstructured":"Lee S. Safety of alefacept in patients who are refractory or have contraindications to other psoriasis therapies: pooled results of phase 3 studies. Presented at Academy '03. Chicago, July 25\u201329, 2003"},{"issue":"6","key":"10.1016\/j.det.2004.03.014_BIB37","first-page":"778","article-title":"The risk of malignancy associated with psoriasis","volume":"137","author":"Margolis","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2004.03.014_BIB38","doi-asserted-by":"crossref","unstructured":"Mariette X., Cazals-Hatem D., Warszawki J., Liote F., Balandraud N., Sibilia J, and the investigators of the Club Rhumatismes et Inflammation. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002;99:3909\u201315","DOI":"10.1182\/blood.V99.11.3909"},{"key":"10.1016\/j.det.2004.03.014_BIB39","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0190-9622(03)01836-X","article-title":"CD4+ T-cell\u2013directed antibody responses are maintained in psoriatic patients receiving alefacept: results of a randomized study","volume":"49","author":"Gottlieb","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2004.03.014_BIB40","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1086\/315739","article-title":"Evaluation of CD4+ T cell function in vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization","volume":"182","author":"Fogelman","year":"2000","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.det.2004.03.014_BIB41","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1172\/JCI106756","article-title":"Immunologic responses to bacteriophage \u03c6X 174 in immunodeficiency diseases","volume":"50","author":"Ochs","year":"1971","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.det.2004.03.014_BIB42","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/0090-1229(89)90024-X","article-title":"Human antibody responses to bacteriophage \u03c6X174: sequential induction of IgM and IgG subclass antibody","volume":"51","author":"Pyun","year":"1989","journal-title":"Clin Immunol Immunopathol"},{"issue":"4","key":"10.1016\/j.det.2004.03.014_BIB43","doi-asserted-by":"crossref","first-page":"F55","DOI":"10.1097\/00002030-200003100-00004","article-title":"Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage \u03c6X174 in asymptomatic HIV-1 infected patients","volume":"14","author":"Rubinstein","year":"2000","journal-title":"AIDS"},{"issue":"8057","key":"10.1016\/j.det.2004.03.014_BIB44","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0140-6736(78)90612-8","article-title":"Immune response after splenectomy","volume":"1","author":"Sullivan","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.det.2004.03.014_BIB45","first-page":"1075","article-title":"A study of combination therapy with alefacept and ultraviolet B light for treatment of psoriasis [abstract 79]","volume":"147","author":"Ortonne","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2004.03.014_BIB46","unstructured":"Koo J.Y.M. Combination therapy with alefacept plus broadband ultraviolet B light for treatment of psoriasis. Presented at the Ninth International Psoriasis Symposium. New York, June 18\u201322, 2003"},{"key":"10.1016\/j.det.2004.03.014_BIB47","first-page":"218","article-title":"Repeated courses of IM alefacept in psoriasis: rationale and design of an international study that mimics the clinical practice setting","volume":"121","author":"Krueger","year":"2003","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.det.2004.03.014_BIB48","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.4049\/jimmunol.166.4.2878","article-title":"Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions that appear antigen driven","volume":"166","author":"Costello","year":"2001","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.det.2004.03.014_BIB49","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/ard.57.11.691","article-title":"T cell derived cytokines in psoriatic arthritis synovial fluids","volume":"57","author":"Partsch","year":"1998","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.det.2004.03.014_BIB50","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0198-8859(99)00034-8","article-title":"Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis","volume":"60","author":"Tassiulas","year":"1999","journal-title":"Hum Immunol"},{"issue":"10","key":"10.1016\/j.det.2004.03.014_BIB51","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1002\/art.10543","article-title":"Alefacept treatment in psoriatic arthritis. Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis","volume":"46","author":"Kraan","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.det.2004.03.014_BIB52","doi-asserted-by":"crossref","first-page":"908","DOI":"10.7326\/0003-4819-136-12-200206180-00012","article-title":"Rheumatoid arthritis\u2014a molecular understanding","volume":"136","author":"Smith","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.det.2004.03.014_BIB53","unstructured":"Schneider M., Stahl H.-D., Vaishnaw A., Podrebarac T., Juergen B. A pilot study of the safety and efficacy of alefacept in subjects with active rheumatoid arthritis on methotrexate [abstract OP0111]. Presented at the Fourth Annual European Congress of Rheumatology. Lisbon, Portugal, June 18\u201321, 2003 [abstract available at: http:\/\/www.eular.org. Accessed May 2003]"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863504000233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863504000233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T23:31:31Z","timestamp":1706139091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863504000233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["S0733863504000233"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2004.03.014","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}